PIGR Rabbit Polyclonal Antibody for WB, IF/ICC, IHC-P, ELISA - O70570

Core Product Specifications and Parameters

Biological Background: PIGR Function and Localization

• PIGR (Polymeric Immunoglobulin Receptor) is a single-pass type I membrane protein that mediates the selective transcytosis of polymeric IgA and IgM across mucosal epithelial cells.
• Upon binding polymeric immunoglobulins at the basolateral surface, the receptor-ligand complex is transported across the cell to the apical surface, where proteolytic cleavage releases the extracellular portion as the secretory component.
• Through its N-linked glycans, the secretory component anchors secretory IgA (sIgA) molecules to the mucosal lining, helping to neutralize extracellular pathogens.
• In its free, unliganded form, PIGR may act as a non-specific microbial scavenger, preventing pathogen adherence to epithelial cells.
• PIGR is localized at the cell membrane and is also secreted after cleavage of its extracellular domain.
• The protein contains immunoglobulin-like domains, disulfide bonds, and is subject to N-glycosylation and phosphorylation, which are critical for its stability and function.

Experimental Guidance and Technical Tips

• As a polyclonal antibody, this reagent recognizes multiple epitopes, which may provide robust signal in various applications.
• For immunoblotting (WB), the full-length receptor has a predicted molecular weight of ~83 kDa; cleavage products corresponding to the secretory component may also be observed.
• In immunofluorescence (IF/ICC) and immunohistochemistry (IHC-P), consider using mucosal tissue sections (e.g., small intestine, colon) where PIGR is highly expressed.
• For ELISA, the antibody can be used as a capture or detection reagent when paired with appropriate standards; validate specificity using recombinant PIGR protein.
• Perform appropriate controls, such as tissue from knockout animals or blocking with immunogen, to confirm specificity.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio streamlines your IVD development with a comprehensive portfolio of validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and rare target raw-material sourcing. For polyclonal antibodies targeting key mucosal immunity markers like PIGR, our end-to-end support—from concept to clinic—helps you accelerate assay development and ensure consistent reagent supply.